vTv Therapeutics Q1 2025 net loss $5.1M; cash $31.1M; cadisegliatin Phase 3 data expected 2H 2026

vTv Therapeutics Inc.

Net loss attributable to shareholders was $5.1M ($0.77 per share) vs $4.9M ($1.17 per share) in Q1 2024.
Cash at March 31, 2025: $31.1M, down from $36.7M at December 31, 2024.
Revenue was $0 compared to $1.0M in the prior-year period.
Phase 3 CATT1 trial for cadisegliatin shortened from 12 to 6 months; topline data expected in 2H 2026.
R&D expenses $2.8M, G&A $3.7M; operating loss of $6.5M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.